UCLA Health researchers unveil major advances in breast cancer AI pathology, liquid biopsy, and biomarker strategies at the 2025 SABCS.
Key Details
- 12025 San Antonio Breast Cancer Symposium features UCLA-led research in early detection, precision medicine, and artificial intelligence.
- 2A study of 2,200+ breast cancer cases showed an AI tool (Ataraxis Breast) surpassed current criteria in identifying high-risk HR+/HER2– patients for CDK4/6 therapy.
- 3Research using liquid biopsy (ctDNA) found negative results were linked to less anxiety and greater well-being in survivors.
- 4Simple immune blood markers before treatment predicted pathologic response to neoadjuvant immunotherapy in triple-negative breast cancer.
- 5AI-driven pathology may refine treatment selection, and liquid biopsies show promise in both outcomes tracking and patient support.
Why It Matters
These advances suggest AI and blood-based diagnostics may dramatically improve risk stratification, treatment selection, and quality of life in breast cancer care. The findings point to imminent shifts in clinical workflows and highlight the growing role of artificial intelligence in precision oncology.
Source
EurekAlert
Related News
•EurekAlert
AI and Advanced Microscopy Unveil Cell's Exocytosis Nanomachine
Researchers have discovered the ExHOS nanomachine responsible for constitutive exocytosis using advanced microscopy and AI-enhanced image analysis.
•EurekAlert
Physical Activity Linked to Breast Tissue Biomarkers in Teens
A study links adolescent recreational physical activity to changes in breast tissue composition and stress biomarkers, potentially impacting future breast cancer risk.
•EurekAlert
AI Reveals Key Health System Levers for Cancer Outcomes Globally
AI-based analysis identifies the most impactful policy and resource factors for improving cancer survival across 185 countries.